

Investor Contact:

Robert G. Burrows
Vice President, Investor Relations
240-631-3280
BurrowsR@ebsi.com

Media Contact:

Tracey Schmitt Lintott
Senior Vice President, Global Public Affairs
240-631-3394
SchmittT@ebsi.com

EMERGENT BIOSOLUTIONS TO PARTICIPATE IN THE BANK OF AMERICA MERRILL LYNCH HEALTHCARE CONFERENCE IN MAY 2016

GAITHERSBURG, MD, April 26, 2016—Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company's senior management team will participate in the Bank of America Merrill Lynch Healthcare Conference, May 10-12, 2016 in Las Vegas, NV.

Presentation date and time will be updated on the Emergent website www.emergentbiosolutions.com under "Investors" as this information becomes available.

For this conference, the company will be webcasting its presentation, which may include a discussion of the company's recent business developments as well as its most recently reported financial results and guidance. The webcast will be available both live and by replay, accessible from the Emergent website www.emergentbiosolutions.com under "[Investors](#)."

About Emergent BioSolutions Inc.

Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. We also develop and commercialize therapeutics and other specialty products for hospitals and clinics in the areas of hematology/oncology, transplantation, infectious diseases and autoimmune disorders. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at www.emergentbiosolutions.com. Follow us [@emergentbiosolu](https://twitter.com/emergentbiosolu).

###